Description du projet
La technologie micro-ondes appliquée au dépistage du cancer du sein
Dans de nombreux pays, le dépistage du cancer du sein chez les femmes de plus de 40 ans qui courent le risque de développer la maladie est effectué au moyen d’une mammographie, une technique fondée sur les rayonnements ionisants. Bien qu’elle facilite la détection du cancer du sein à un stade précoce, cette technologie n’est pas adaptée aux seins denses sur le plan radiographique. Pour surmonter cette contrainte, le projet MammoScreen, financé par l’UE, propose d’utiliser MammoWave pour le dépistage du cancer du sein, une technologie non invasive qui utilise des signaux micro-ondes non ionisants. Contrairement à la mammographie, la technologie de MammoWave n’applique aucune compression sur le sein et est très efficace avec les seins denses, ce qui la rend adéquate pour les jeunes femmes de moins de 40 ans.
Objectif
Breast cancer (BC) is the most common cancer in women worldwide, affecting 1 in 8 women. The figures from WHO’s International Agency for Research on Cancer estimate that in 2020 worldwide cases of breast cancer accounted for 24% of all cancers in women (2.26 million women and 685,000 deaths globally). Mammography is the gold standard technology for breast screening, which has been demonstrated through different randomized controlled trials to reduce breast cancer mortality. However, it has limitations and potential harms, such as the use of ionizing radiation, breast compression and performance restrictions due to the intrinsic nature of X-rays. In particular, breast density is a restrictive property that can prevent breast cancer detection in mammograms of women with radiographically dense breasts. Other existing techniques (MRI, Ultrasound, biopsy) also suffer from drawbacks. The overall aim of the MammoScreen proposal is to generate evidence about the use of MammoWave (a technology developed by UBT) as screening technique in population-based programs promoted by National or Regional Health Systems, to reach a revolution in breast screening. To do so, the consortium aims to confirm that MammoWave reaches sensitivity>90% and specificity>95% in BC detection on 10000 study participants undergoing regular screening programs. MammoWave uses safe non-invasive and non-ionizing microwave signals, does not apply any compression to the breast and is very effective with dense breasts. Hence it can extend the breast screening to younger women aged 20-49 (98 million women in Europe). This group accounts for ~30% of breast cancers in 2020. A comprehensive health economic assessment will be undertaken in this project and innovative way to implement patient engagement approaches is sought. An effective policy makers’ engagement plan will be carried out to ensure that MammoWave is recommended as screening approach due to the benefits that it brings to women and healthcare systems. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening.
Champ scientifique
Programme(s)
- HORIZON.2.1 - Health Main Programme
Régime de financement
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinateur
53100 Siena
Italie